Limitations, agreements, and source contact

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer · Source last updated 2022-06-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

OTHER

restrictive Agreement

true

point Of Contact

email

clinical-trials-contact@bayer.com

organization

Bayer

phone

1-888-8422937

title

Therapeutic Area Head

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice